Business Context and Reporting Period
This Form 8-K is a current report filed by Akers Biosciences, Inc. on November 13, 2020. The filing addresses an update regarding a previously disclosed private placement and its relationship to a pending merger agreement with MyMD Pharmaceuticals, Inc.
Key Financial Metrics
The filing discloses the following financial details regarding the private placement:
- Transaction Type: Private placement of common stock and warrants.
- Shares Issued: 9,765,933 shares of common stock.
- Warrants Issued: Warrants to purchase 9,765,933 shares of common stock.
- Gross Proceeds: Approximately $18.1 million.
The filing does not provide data on revenue, profit, operating cash flow, margins, existing debt levels, or general liquidity metrics beyond the proceeds from this specific transaction.
Material Changes
The primary material change reported is a revision to the closing timeline of the private placement:
- Prior Disclosure: The company previously stated the private placement would close simultaneously with the consummation of the merger with MyMD Pharmaceuticals, Inc.
- Current Update: The private placement is now expected to close on or around November 16, 2020, independent of the immediate consummation of the merger.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on future operations, or specific risk factors beyond the operational update regarding the transaction closing date. No unusual items or contingencies are detailed in this specific report.
Investor Verification Checklist
- Verify the actual closing date of the private placement (expected November 16, 2020).
- Confirm the status of the Agreement and Plan of Merger with MyMD Pharmaceuticals, Inc.
- Review the terms of the warrants issued alongside the common stock.
- Check subsequent filings for the final confirmation of the $18.1 million gross proceeds.